PDS Biotechnology Corp (PDSB) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. PDS Biotechnology Corp is a clinical-stage immunotherapy company developing targeted cancer immunotherapies (Versamune® and PDS01ADC) and infectious disease candidates (Infectimune®). The company has no commercially approved products and has incurred net losses since inception.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7.35) million | $(8.49) million |
| Net Loss Per Share (Basic/Diluted) | $(0.13) | $(0.21) |
| Cash and Cash Equivalents (End of Period) | $21.66 million | $39.98 million |
| Operating Cash Flow | $(4.37) million | $(9.03) million |
| Total Debt (Current + Noncurrent) | $15.81 million | Filing text does not provide clear Q1 2025 total debt value |
| Stockholders' Equity | $3.89 million | $22.36 million |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 28% to $6.52 million from $9.11 million. Research and Development (R&D) expenses dropped 41% to $3.46 million, driven by lower clinical trial, manufacturing, and personnel costs.
- Interest Expense: Net interest expense increased to $0.83 million (from $0.55 million) due to higher amortization of debt discounts on convertible debentures issued in 2025.
- Loss of Tax Benefit: The company recorded no income tax benefit in Q1 2026, compared to a $1.17 million benefit in Q1 2025. This is due to reaching the statutory $20 million lifetime cap on New Jersey Net Operating Loss (NOL) sales.
- Financing Activity: The company generated $0.83 million from its at-the-market (ATM) program but made $1.5 million in principal repayments on convertible debentures, resulting in a net cash outflow from financing activities of $0.68 million.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least 12 months from the filing date due to recurring losses and negative cash flows.
- Clinical Progress: The company is advancing the VERSATILE-003 Phase 3 trial for PDS0101 in HPV16-positive head and neck cancer. In February 2026, the protocol was amended to include progression-free survival (PFS) as an interim primary endpoint to support potential accelerated approval.
- Debt Covenants: The company is subject to restrictive covenants on its $22.2 million convertible debentures, including a requirement to maintain a minimum cash balance (lesser of $15 million or principal + $3 million). Failure to maintain this balance could trigger a call on the debt.
- Subsequent Events: On April 30, 2026, the company entered into an agreement to issue a $6 million promissory note and warrants to a new investor. Additionally, the company elected to prepay all outstanding debentures (at 103% of principal) upon the closing of this new transaction, expected around June 12, 2026.
Investor Verification Checklist
- Cash Runway: Verify if the $21.7 million cash balance is sufficient to fund operations until the anticipated closing of the $6 million note in June 2026, considering the mandatory monthly debt repayments.
- Debt Prepayment Terms: Confirm the exact closing conditions for the new $6 million note and the mechanics of the 103% prepayment of the existing debentures.
- ATM Termination: Note that the previous At-The-Market sales agreement was terminated on May 1, 2026; verify the terms and capacity of the new sales agreement mentioned in subsequent events.
- Clinical Milestones: Monitor the FDA Type C meeting outcomes and the interim analysis results of the VERSATILE-003 trial, which are critical for future valuation and funding.